A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants
A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SEP-479 in Healthy Adult Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Melbourne, Australia
- Recruiting
- Nucleus Network
-
Contact:
- Nucleus Network Melbourne
- Phone Number: 1800 243 733
- Email: melbourne@nucleusnetwork.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects who are able and willing to provide informed consent
- Aged 21 to 60 years at the time of consent
- Have a BMI within the range 18.0 to 32.0 kg/m2
- In general good health
Exclusion Criteria:
- Any condition, which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol.
- Have clinically significant abnormalities on clinical laboratory results.
- Participation in other clinical trials recently/currently
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Food Effect
|
Oral, capsule
|
|
Experimental: Single Ascending Dose
|
Oral, capsule
Oral, capsule
|
|
Experimental: Multiple Ascending Dose
|
Oral, capsule
Oral, capsule
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Frequency of treatment emergent adverse events
Time Frame: From enrollment to end of follow up visit, up to approximately 2 months
|
From enrollment to end of follow up visit, up to approximately 2 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma PK of SEP-479 after single and multiple doses
Time Frame: From enrollment to end of treatment period, up to approximately 14 days
|
Maximum Plasma Concentration (Cmax) of SEP-479
|
From enrollment to end of treatment period, up to approximately 14 days
|
|
Plasma PK of SEP-479 after single and multiple doses
Time Frame: From enrollment to end of treatment period, up to approximately 14 days
|
Elimination half-life (T 1/2) of SEP-479
|
From enrollment to end of treatment period, up to approximately 14 days
|
|
Plasma PK of SEP-479 under fed and fasted conditions
Time Frame: From enrollment to end of treatment period, up to approximately 14 days
|
Maximum Plasma Concentration (Cmax) of SEP-479
|
From enrollment to end of treatment period, up to approximately 14 days
|
|
Plasma PK of SEP-479 after single and multiple doses
Time Frame: From enrollment to end of treatment period, up to approximately 14 days
|
Area Under the Concentration-time Curve (AUC) of SEP-479
|
From enrollment to end of treatment period, up to approximately 14 days
|
|
Plasma PK of SEP-479 under fed and fasted conditions
Time Frame: From enrollment to end of treatment period, up to approximately 14 days
|
Area Under the Concentration-time Curve (AUC) of SEP-479
|
From enrollment to end of treatment period, up to approximately 14 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SEP-479-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.